GHRP-2 Peptide Reduces Muscle Wasting After Burn Injury in Rats
Background
Thermal injury, such as severe burns, triggers a state of hypermetabolism, leading to significant body weight loss and severe skeletal muscle wasting. Previous research has shown that ghrelin, a natural hormone, can stimulate food intake, promote growth hormone release, and inhibit muscle breakdown in thermally injured rats. However, the need remains for a more stable, lower molecular weight, and longer-acting peptide to effectively combat these severe catabolic responses; this study specifically investigates if the ghrelin mimetic, growth hormone-releasing peptide-2 (GHRP-2), can attenuate the muscle breakdown caused by thermal injury.
Results
The study revealed that GHRP-2 treatment significantly attenuated several markers of muscle wasting in thermally injured rats. Specifically, it prevented the burn injury-induced increase in mRNA expression of the inflammatory cytokine IL-6, and crucially, the E3 ubiquitin ligases MuRF-1 and MAFbx in rat skeletal muscle. These ligases are key enzymes involved in targeting proteins for degradation, so their reduced expression indicates a direct impact on the muscle breakdown pathway. GHRP-2 treatment effectively attenuated the burn-induced increases in both total protein breakdown and myofibrillar protein breakdown in the rat EDL muscle, demonstrating a direct protective effect against muscle loss. This suggests that GHRP-2 actively counteracts the severe catabolic state induced by thermal injury, preventing the accelerated breakdown of muscle tissue compared to untreated burn-injured controls.
Why It Matters
This research highlights a significant potential for GHRP-2 as a therapeutic agent to combat the debilitating muscle wasting associated with severe thermal injuries. By attenuating the expression of key muscle breakdown enzymes and directly reducing protein degradation, GHRP-2 offers a novel strategy to preserve muscle mass and improve recovery outcomes in burn patients. These findings strongly suggest that GHRP-2 could be developed into a crucial clinical intervention to mitigate the severe catabolic responses and muscle loss experienced by individuals suffering from extensive burns. Future steps should involve further preclinical optimization and eventually, human clinical trials to confirm its efficacy and safety in a clinical setting.